Genelabs Technologies, Inc.

Genelabs Technologies, Inc. is engaged in drug discovery, dedicated to developing new candidate medications through a combination of classical pharmacology and modern techniques. It primarily serves pharmaceutical companies and research institutions globally. Founded in 1983, Genelabs Technologies, Inc.

operates out of Redwood City, US. The company specializes in drug discovery and has undergone a significant shift in operations leading to its acquisition by GlaxoSmithKline Plc in January 2009 for USD 57 mn. The firm has facilitated three deals since its inception, reflecting its ongoing commitment to advancing therapeutic solutions. The CEO is Christos Loutradis, whose leadership continues to steer the company's innovative pursuits within the pharmaceutical sector.

Genelabs Technologies, Inc. specializes in drug discovery, focusing on developing new candidate medications through a meticulous process that integrates classical pharmacology with modern techniques. Their core offerings include high throughput screening of extensive compound libraries against isolated biological targets, which are poised to demonstrate disease-modifying effects. This approach enables the efficient identification and optimization of promising drug candidates across various parameters, including affinity, selectivity, potency, metabolic stability, and oral bioavailability.

The company aims to tackle significant health challenges associated with chronic and infectious diseases, marketing its services primarily to pharmaceutical companies and research institutions in North America, Europe, and Asia. Genelabs generates revenue through partnerships with pharmaceutical firms and research institutions, offering drug discovery services in exchange for financial compensation and potential royalties on successful drug candidates. Their revenue model is structured around contracts for specific research projects or ongoing collaborations tailored to mutual goals. While specific pricing details are not disclosed, the company effectively capitalizes on the high demand for drug discovery solutions in a competitive industry, leveraging proprietary methodologies integral to their partnered drug development efforts.

Following its acquisition by GlaxoSmithKline in January 2009, Genelabs Technologies, Inc. is focused on optimizing its existing product offerings and expanding its footprint in drug discovery. Although current details on upcoming product launches are not specified, the strategic utilization of the USD 57 mn from the latest funding round will likely support enhancements in their research capabilities and outreach to new geographic markets. The company is expected to target expansion into emerging markets in Asia and Europe by 2025, aligning with industry trends toward innovative therapeutic development.